Quick filters
50 Matches
1
2
- Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients with Rare Form of Blood Disease Business Wire | Monday June 17, 2013 1:30AM
- Oral Apremilast Achieves Statistical Significance for Primary and Secondary Endpoints in a Phase II Trial in Patients with Behçet's Disease Business Wire | Friday June 14, 2013 6:04AM
- Data from Phase III Randomized Controlled Study (PALACE 3) of Apremilast in Psoriatic Arthritis Presented at EULAR Business Wire | Thursday June 13, 2013 4:30AM
- Celgene Announces Additional $3.0 Billion Share Repurchase Program Business Wire | Wednesday June 12, 2013 8:00AM
- Signs and Symptoms of Psoriatic Arthritis Significantly Improved in Patients Receiving Long-Term Oral Apremilast Treatment in Phase III Study (PALACE-1) Business Wire | Wednesday June 12, 2013 7:30AM
- Celgene Corporation to Webcast at Upcoming Investor Conference Business Wire | Thursday June 6, 2013 8:00AM
- U.S. Food and Drug Administration Approves REVLIMID® (lenalidomide) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma Business Wire | Wednesday June 5, 2013 1:00PM
- Analyses of MPACT Trial Evaluating ABRAXANE® Combination Therapy for the Treatment of Advanced Pancreatic Cancer Presented at ASCO 2013 Business Wire | Monday June 3, 2013 12:30PM
- Celgene Announces Launch of “Innovation Impact” Awards to Recognize Excellence in Creative Patient, Caregiver or Healthcare Provider Programs Business Wire | Friday May 31, 2013 8:30AM
- Oral Anti-Cancer Therapy Pomalidomide Celgene Receives Positive CHMP Opinion as Treatment for Patients with Relapsed and Refractory Multiple Myeloma Business Wire | Friday May 31, 2013 6:22AM
- Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA in Advanced Pancreatic Cancer Business Wire | Thursday May 23, 2013 12:09PM
- Four biotech stocks that outperform the market Globe and Mail | Friday May 10, 2013 1:47PM
- Apremilast Achieves Statistical Significance for the Primary and Major Secondary Endpoints in Fourth Pivotal Phase III Study (PALACE 4) of Patients with Psoriatic Arthritis Business Wire | Monday May 6, 2013 2:27PM
- Biotech is back, and no longer bubblicious Globe and Mail | Friday May 3, 2013 9:37AM
- Celgene Corporation to Webcast at Upcoming Investor Conferences and Analyst Day Business Wire | Monday April 29, 2013 8:30AM
- UPDATE 1-EU body backs new Roche, Astellas, Sanofi, Vivus drugs Globe and Mail | Friday April 26, 2013 8:24AM
- UPDATE 1-Celgene raises 2013 profit forecast, shares rise Globe and Mail | Thursday April 25, 2013 8:48AM
- Celgene profit beats estimates as demand for cancer drugs rise Globe and Mail | Thursday April 25, 2013 7:43AM
- Celgene Reports First Quarter 2013 Operating and Financial Results Business Wire | Thursday April 25, 2013 7:29AM
- Celgene Corporation to Announce First Quarter 2013 Results on April 25, 2013 Business Wire | Wednesday April 3, 2013 7:30AM
1
2
Live Discussion of CELG on StockTwits